Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib for Food Allergy Prevention
NCT05038904Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib tablet (Variant 1) in food allergy, sponsored by Johns Hopkins University. Primary endpoint: Highest Dose of Peanut That is Tolerated During Oral Food Challenge at Day 2. Started Dec 2021; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT05038904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038904.